The predictive value of methylene blue dye as a single technique in breast cancer sentinel node biopsy: a study from Dharmais Cancer Hospital

Bayu Brahma1,3*, Rizky Ifandriani Putri2, Ramadhan Karsono1,4, Bob Andinata1, Waltu Gautama1, Lenny Sari2 and Samuel J. Haryono1,4

Abstract

Background: Axillary lymph node dissection (ALND) has been the standard treatment of breast cancer axillary staging in Indonesia. The limited facilities of radioisotope tracer and isosulfan or patent blue dye (PBD) have been the major obstacles to perform sentinel node biopsy (SNB) in our country. We studied the application of 1% methylene blue dye (MBD) alone for SNB to overcome the problem.

Methods: This prospective study enrolled 108 patients with suspicious malignant lesions or breast cancer stages I–III. SNB was performed using 2–5 cc of 1% MBD and proceeded with ALND. The histopathology results of sentinel nodes (SNs) were compared with axillary lymph nodes (ALNs) for diagnostic value assessments.

Results: There were 96 patients with invasive carcinoma from July 2012 to September 2014 who were included in the final analysis. The median age was 50 (25–69) years, and the median pathological tumor size was 3 cm (1–10). Identification rate of SNs was 91.7%, and the median number of the identified SNs was 2 (1–8). Sentinel node metastasis was found in 53.4% cases and 89.4% of them were macrometastases. The negative predictive value (NPV) of SNs to predict axillary metastasis was 90% (95% CI, 81–99%). There were no anaphylactic reactions, but we found 2 cases with skin necrosis.

Conclusions: The application of 1% MBD as a single technique in breast cancer SNB has favorable identification rates and predictive values. It can be used for axillary staging, but nevertheless the technique should be applied with attention to the tumor size and grade to avoid false negative results.

Keywords: Sentinel node, Breast cancer, Axillary lymph node, Methylene blue dye

Background

Breast cancer is the most common malignancy, accounting for 31.2% of all cancers and 26.5% as the cause of cancer death among women in our hospital [1]. In Asia-Pacific region, 12% of breast cancer incidence rates and 17% of its death occur in Indonesia [2]. The information of axillary lymph node (ALN) metastasis is one of the most important prognostic factors in breast cancer treatments. It is conventionally determined by axillary lymph node dissection (ALND) [3, 4]. This procedure gives morbidities such as lymphedema, loss of sensory, limited mobility, and seroma formation which will decrease the quality of life [4–6]. Nowadays, breast cancer treatments have moved towards conservation therapies, and sentinel node biopsy (SNB) has been introduced as a part of the minimal invasive breast surgery [3, 7]. Unfortunately, ALND is still the standard procedure for axillary staging in Indonesia. The limitation to provide sophisticated technologies for SNB has been our mainstay issue.
The work by Morton et al. [8] in cutaneous melanoma was the turning point of the acceptance of the sentinel node (SN) concept. It was soon adopted to breast cancer patients by using isosulfan blue dye or radioisotope tracer alone to find SNs. Initially, the reported identification rates of SNs ranged between 65 and 98% and false negative rates between 0 and 5% [9–12]. In developed countries, the optimal technology for SNB uses isosulfan or patent blue dye (PBD), preoperative lymphoscintigraphy, and radioisotope tracer, which are used as a single or combination technique [9–13]. As an alternative to these devices, several studies have been conducted to validate 1% methylene blue dye (MBD) for SNB. Simmons [14] was the first surgeon who reported the successful application of 1% MBD in breast cancer SNB. The other studies also supported its use because of the favorable results in identification and false negative rates, fewer allergic complications, and lower cost [15–22].

Limited access to PBD and radioisotope tracer is the main problem to perform SNB in Indonesia. Not to mention our geographic distribution of the population, the availability and cost to provide nuclear medicines, or gamma probes in every hospital have contributed to the difficulty for administering SNB. Recently, we have started to use 1% MBD alone, and the initial results from 24 patients were favorable with the identification rates of 95.8% [23]. As we have moved towards better breast cancer care, it is important for us to conduct a study to overcome the limitation to perform SNB. The primary objective of the study is to evaluate the identification rates and negative predictive value (NPV) of SNs to predict axillary metastasis by using 1% MBD alone.

Methods

Participants

In this study, 108 consecutive patients with diagnosis of breast cancer or suspicious malignancy were enrolled prospectively at Dharmais Cancer Hospital, Bogor City General Hospital, and Mochtar Riady Comprehensive Cancer Center (MRCCC) Siloam Hospital between July 2012 and September 2014. There were five surgeons participating in the research. SJH, RK, and WG had more than 5 years of experience, while BB and BA had more than 3 years of experience in breast cancer surgery including ALND. All surgeons had less than 10 cases in performing MBD technique alone prior to the study. BB, RK, and SJH were also the surgeons who were working and undertaking SNB in the other participating hospitals besides Dharmais Cancer Hospital. We included patients with any tumor size (T) without palpable ALNs (cNo) and had performed core needle or fine needle aspiration (FNA) biopsy. Patients without final pathological results of invasive breast cancer or had a pregnancy were excluded from the study. The Institutional Review Board at Dharmais Cancer Hospital approved the study, and all patients were provided informed consent.

Sentinel node biopsy and axillary lymph node dissection

SNB was performed using 1% MBD. It was injected in a subareolar or peritumoral area with the dose of 2 until 5 cc. We did a peritumoral injection in all cases with previous excisional biopsy at the upper outer quadrant of the breast or according to the surgeon’s preferences. A breast massage was done for 5 min after the injection. In a standard breast conserving or oncoplastic breast conserving surgery (BCS), a separate incision in the lower axillary hairline was made to find SNs before lumpectomy or quadrantectomy. When the patients underwent mastectomy, SNB was undertaken through the same mastectomy incision before removing the breast. Sentinel nodes were defined as blue nodes or lymph nodes with a lymphatic blue channel. All procedures proceeded to ALND levels I–II. Axillary lymph node dissection level III was done when there were suspicious lymph node metastases at level II. If a frozen section were available, it would be used to assess an intraoperative SN metastasis. Histopathological results of all ALNs were collected after the surgery.

Pathological examination

The sentinel nodes were surgically removed at the beginning of the surgical procedure and sent for a standard pathological assessment or frozen-section examination if available. The sentinel nodes were sectioned no thicker than 2 mm and parallel to the long axis. An intraoperative analysis was categorized to positive or negative for metastases. The rest of SNs were formalin fixed and paraffin sectioned with hematoxyline-eosin staining.

The tumors were histologically classified according to the World Health Organization (WHO) Histological Classification of Breast Tumors, and grading was defined according to Elston and Ellis modification [24]. All specimens were reviewed in Dharmais Cancer Hospital by two pathologists (RIP and LS). Only 2 patients who underwent surgery at MRCCC hospital were not reviewed due to the patients’ preference and thus analyzed by using the original histopathology report from the local pathologist. Molecular subtypes for invasive cancer were classified as luminal A (ER+ and/or PR+, HER2−), and histological grade either 1 or 2), luminal B (ER+ and/or PR+, HER2+; or ER+ and/or PR+, HER2− and grade 3), triple negative (ER−, PR−, HER2−), and HER2+ (ER−, PR−, HER2+) [25].

The nodal involvement was classified according to the 6th edition of the American Joint Committee on Cancer (AJCC) manual. Macrometastasis (MAC) is defined as tumor deposits larger than 2 mm, micrometastasis (MIC) if tumor deposits between 0.2 and 2.0 mm, and
isolated tumor cells (ITCs) if there are cell clusters or a single cell no larger than 0.2 mm. Serial sections and immunohistochemistry (IHC) for cytokeratin were performed when there was some doubt to define ITCs. The rest of ALNs were also examined in a similar manner. The histopathology of SNs was compared to the final examination of ALNs for the presence of metastases [24, 26].

Statistical analysis
Descriptive data were presented in the table of frequency. Sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) were calculated using CATmaker. Diagnostic values were reported with 95% confidence of interval (CI). We used SPSS version 16.0 to manage the data.

Results
Patient characteristics
We prospectively enrolled 108 patients from July 2012 to September 2014. Twelve patients with FNA biopsy result of suspicious breast cancer were excluded because the frozen section and final pathological results were not invasive carcinoma. There were 87 (90.6%) patients from Dharmais Cancer Hospital and 9 (9.4%) from the other hospitals. Of the 96 patients who were included in the final analysis, the median age was 50 years (range 25–69 years). There were 9 (9.4%) patients in stage I, 64 (66.7%) in stage II, and 23 (23.9%) in stage III. The median pathological tumor size was 3 (1–10) cm. Invasive carcinoma of no special type (NST) was the most common result which accounted for 71 (74%) patients and invasive lobular carcinoma (ILC) in 11 (11.5%) patients. We classified breast cancer molecular profile based on IHC examination. Thirty-eight (39.6%) patients were classified as luminal A breast cancer, 24 (25%) as luminal B, 10 (10.4%) as HER2+ type, and 24 (25%) as triple negative (TNBC). Mastectomy was the most common surgical procedure which was done in 60 (62.5%), meanwhile BCS in 36 (37.5%) patients. Table 1 summarizes the characteristic of patients.

Sentinel node biopsy and pathological examination
We could identify SNs in 88 patients. Therefore, the SNs identification rate was 91.7%. Peritumoral injections were done in 29 (30.2%) and subareolar in 67 (69.8%) cases. The median number of SNs that could be identified was 2 (1–8) and the median of ALNs was 11 (5–27). In this group where SNs were identified, the number of SNs without metastases was 41. Four of these patients were found to have metastases in non-sentinel nodes (NSNs), and so the total patients without lymph node metastases were 41. Four of these patients were found to have metastases in non-sentinel nodes (NSNs), and so the total patients without lymph node metastases were 37 (42%). There were 47 (53.4%) cases with SN metastases and 42 (89.4%) of them had MAC. The number of SN metastases which was only found in 1–2 SNs was 43 (91.5%), whereas 4 (8.5%) metastases were identified in more than 2 SNs. We discovered 25 (53.2%) cases with additional metastatic deposits in NSNs. Therefore, in 22 (46.8%) patients, the metastases only occurred in SNs. Table 2 describes the cases with positive SNs. The SNs detected metastases in 47 of 51 cases, resulting in a Se of 92% (95% CI, 85–100%), and there were 4 NSN metastases in the SN negative group which resulted in a NPV of 90% (95% CI, 81–99%). All 4 cases that failed to predict ALN metastases had a median pathological tumor size of 4 cm, 2 patients in stage IIB and the others were in stage IIIA. Three (75%) patients were grade 3 invasive carcinoma. Figure 1 and Table 3 show the recruitment of patients and results of diagnostic value. Table 4 describes the false negative patients.

Unidentified sentinel nodes
The SNs could not be found in 8 patients. The median age of the patients was 54 years old (range 36–67 years) with the median tumor size of 2.8 (1.5–5.0) cm. There were 2 (25%) grade 1, 3 (37.5%) grade 2, and 3 (37.5%) grade 3 invasive carcinoma. Two (25%) patients had...
lymph node metastases and the rest were negative. Table 5 describes the characteristic of the unidentified SN group.

**Complications**

Two patients experienced skin necrosis around the injection site after 5 cc of peritumoral injection. They were mastectomies cases one of whom had a breast reconstruction. These patients successfully underwent conservative wound treatment. We found no systemic anaphylactic reactions among all patients.

**Discussion**

The paradigm of early breast cancer management has changed toward conservation treatments, and SNB has replaced ALND in terms of axillary staging [27, 28]. In comparison with developed countries, the majority of breast cancer cases in our country are in locally advanced stages [29]. This is the reason why ALND has become a common practice among our surgeons. Nowadays, we have been expecting to treat patients in early stages since the improvement in our national health care insurance and this condition will motivate us to promote SNB. Although the standard for lymphatic mapping supports the combination technique [13, 30], limited access to radioisotope tracers, PBD, and nuclear medicine facilities have become our obstacles. Our population is distributed across islands and not every hospital has sophisticated technologies for SNB. Therefore, we try to overcome this problem by applying 1% MBD alone for SN identification.

The issue of PBD limitation was solved by several authors with the utilization of 1% MBD which had favorable results [17, 21, 31]. The identification rate of 92% from our research was acceptable when it was compared with the other studies that used MBD [14–17, 19–21]. Another research which supported our result was confirmed by Liu et al. in their randomized controlled study in cutaneous melanoma. They found that MBD was as effective as isosulfan blue dye to identify SNs [32]. The median SN number, which was 2 nodes from our study, was equal with the studies that suggested to find 2 until 3 SNs to minimize the false negative rate [33–37].

In the identified SN group, 42% of the cases were lymph node negative for metastases. It means that there were many cases which were not supposed to receive ALND and we could have saved a lot of patients from having the risk of lymphedema and other morbidities. We believe if our surgeons can apply this SNB technique instead of routine ALND, we will make a better quality of life after the surgery and overall reduce the cost of

---

**Table 3** Diagnostic value of sentinel nodes (n = 88)

| Se   | Sp   | PPV  | NPV  |
|------|------|------|------|
| 92%  | 100% | 100% | 90%  |
| 95% CI (85–100) | 95% CI (100–100) | 95% CI (100–100) | 95% CI (81–99) |

Se sensitivity, Sp specificity, PPV positive predictive value, NPV negative predictive value, CI confidence interval

---

**Table 4** Characteristics of patients with false negative SN (n = 4)

| Patient characteristics | Number | Percentage |
|-------------------------|--------|------------|
| Age (years) Median (range) | 4 | 44 (35–59) |
| Tumor size Median (range) | 4 | 4.0 (3.0–6.0) |
| Pathology | | |
| NST | 4 | 100.0 |
| Molecular subtypes | | |
| Luminal B | 3 | 75.0 |
| Triple negative | 1 | 25.0 |
| Tumor grade | | |
| 2 | 1 | 25.0 |
| 3 | 3 | 75.0 |

NST no special type

---

**Table 5** Characteristics of patients with unidentified SN (n = 8)

| Patient characteristics | Number | Percentage |
|-------------------------|--------|------------|
| Age (years) Median (range) | 8 | 54 (36–67) |
| Tumor size Median (range) | 8 | 2.8 (1.5–5.0) |
| Pathology | | |
| NST | 7 | 87.5 |
| Molecular subtypes | | |
| Luminal A | 4 | 50.0 |
| Ca with medullary feature | 1 | 12.5 |
| HER2 positive | 2 | 25.0 |
| Triple negative | 2 | 25.0 |
| Tumor grade | | |
| 1 | 2 | 25.0 |
| 2 | 3 | 37.5 |
| 3 | 3 | 37.5 |

Metastases in LN Positive 2 25.0

Negative 6 75.0

NST no special type, Ca carcinoma, LN lymph node
breast cancer treatment in Indonesia and its associated surgical morbidities.

The next important findings from our study were the facts that 53% of metastatic foci were found in SNs and nearly half (47%) of them were only confined in SNs. The early publications of SNB in breast cancer have also reported that approximately 50% patients with SN metastases did not have positive NSNs [38, 39]. In this case, the utility of a nomogram to predict NSN metastases [40–43] would become a valuable tool for us.

The Z0011, IBCSG 23-01, and AMAROS studies have given new perspectives to omit ALND after positive SNs [44–46]. According to the studies, patients with a small-sized tumor, plans for BCS, and whole breast radiation are the suitable indications. These selection criteria did not match with the majority of our patient characteristics because it had been shown in this study that we had bigger median tumor size, 24% cases were in stage III, 89% MAC in SNs, and mastectomy was more common than BCS. As we had 91% patients with 1 until 2 metastases in SNs, the POSNOC trial is expected to give us a better evidence for omitting ALND after positive SNs [47], particularly in mastectomy which represents the majority of our cases.

The reported NPV in this study was 90%, and a randomized study from Canavese et al. nearly had the same result (91.1%) [48]. We realized that our NPV was lower than the other studies (92.3 and 96.1%) [49, 50]. It might have been due to the 4 false negative cases which had bigger median tumor size (4 cm) and higher tumor grade (75% in grade 3). So, there were possibilities that tumor size more than 3 cm and high grade tumors had higher risks of volume nodal metastases and blockage of the lymphatic system to SNs and alternates to false SNs [48, 51]. However, when we analyzed separately by excluding stage III patients (data not shown), the NPV would be 95% (95% CI, 80–100%). Thereafter, surgeons must be cautious when performing SNB with MBD alone in a patient with grade 3 and more than 3 cm tumor size. Under these circumstances, looking for additional non blue suspicious lymph nodes is suggested to minimize false negative result.

In this study, SNs could not be found in 8 patients. There are some related factors with the failures to find SNs. The age, body mass index (BMI), tumor size, location, grade, type of previous biopsy, SNB technique, and surgeon’s experience have been reported in literatures as the factors that influence SN identification [52–54]. The median age of the unidentified SN group was 54 years and this older condition could have been one of the factors which accounted for the unsuccessful identification in the final result. The increased fatty tissue in the breast among older patients may decrease lymphatic flow and failures to identify SNs [52, 53].

The surgeon’s experience is another important factor for localizing SNs, especially if blue dye alone is used as the method of choice. Some literatures have explained that identification of SNs will be reduced by less experienced surgeons and the use of blue dye alone technique [53, 54]. Our failure to find SNs might have been explained by these factors as well because in this study, the application of MBD alone was a relatively new technique for us and we did not have many experiences regarding this technique prior to the study.

Higher tumor grade has been known as a negative factor for SN identification in univariate analysis [53]. In our result, grades 2 and 3 tumors constituted about 75% of the cases. Although tumor grade has not been proven as an independent factor for the failure [53], we think it could have contributed to the negative finding in our study.

We experienced two skin necroses around the injection site. Local skin irritation or necrosis after MBD injection was reported by other authors [22, 55]. The toxic effects are due to the formation of aldehydes and a reduction in oxidation products which initiate inflammatory reactions [56]. Although we were not really sure if the skin necrosis was caused by MBD or skin flap necrosis after mastectomy, we decided to lower the dose of injection until 2 cc and we did not have skin necrosis thereafter. We did not find anaphylactic reactions in our cases. The incidence of allergic reactions following PBD was between 0.06 and 2.7% [56]. Whereas anaphylactic reactions following MBD injection was very rare, there were several related serious effects after intrauterine injection [57–60] and pulmonary edema had also been reported after breast cancer SNB in two series [61, 62]. Although MBD can be used safely for lymphatic mapping because of its very rare effects in allergic reactions, we suggest that the operating team should be aware and prepared for the potential anaphylactic reactions of MBD that could happen.

This study has several limitations. First, we only included clinically node negative patients but we did not perform ALN biopsy if the axillary ultrasound found suspicious lymph nodes. Ultrasound-guided axillary lymph node biopsy will select patients with true negative lymph nodes before surgery. Second, blue nodes or non-blue nodes with lymphatic blue channels were the only criteria for SNs. We did not try to find the non-blue suspicious nodes as SNs. These could have reduced our NPV results, especially in cases with high grade and bigger tumor size that could have alternated MBD into the false SNs.

Conclusions
This study has proven that SNB in breast cancer can be performed with 1% MBD alone. It can be done in clinical settings with limited access to perform the standard
combination technique or when PBD is not available. The important factors that should be considered are the following: first, in high grade and bigger tumor size, surgeons must not be satisfied when they only find the blue nodes. The non-blue suspicious lymph nodes must be searched in order to reduce false negative results. Second, a better understanding of the SN anatomic location in the axilla is the key point to increase the identification rate when applying MBD alone technique.

Abbreviations
ALND: Axillary lymph node; MBD: Methylene blue dye; SNB: Sentinel node biopsy

Acknowledgements
The authors would like to thank Adhitya Bayu Perdana and Ali Abdul Aziz for data management and Kuntjoro Harimurti, MD, PhD for data discussion.

Funding
There was no funding support.

Availability of data and materials
Not applicable.

Authors’ contributions
BB, RIP, RK, and SJH participated in the design of this study. BB, RIP, BA, WG, and SJH participated in the concept of this study. RIP and LS performed statistical analysis and drafted the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Dharmais Cancer Hospital ethical committee approved this study.

Author details
1 Department of Surgical Oncology, Dharmais Cancer Hospital, Jalan Let. Jend. S. Parman Kav. 84-86, Jakarta 11420, Indonesia. 2 Department of Anatomical Pathology, Dharmais Cancer Hospital, Jalan Let. Jend. S. Parman Kav. 84-86, Jakarta 11420, Indonesia. 3 Department of Surgical Oncology, Bogor City General Hospital, Jalan DR. Semenu No. 120, West Bogor, West Java 16112, Indonesia. 4 Department of Surgical Oncology, Mochar Rady Comprehensive Cancer Center (MRCCC) Siloam Hospital, Jalan Garnisun Dalam No. 2-3, Semanggi, Central Jakarta 12930, Indonesia.

Received: 19 August 2016 Accepted: 1 February 2017
Published online: 07 February 2017

References
1. Suzanna E, Siai T, Rahayu PS, et al. Registrasi kanker berbasis rumah sakit di rumah sakit kanker "Dharmais"-pusat kanker nasional, 1993-2007. Indonesian J Cancer. 2012;6:179–205.
2. Youlden DR, Cramba SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014;11(2):101–15.
3. Giuliano AE, Han SH. Local and regional control in breast cancer: role of sentinel node biopsy. Adv Surg. 2011;45:101–16.
4. D'Angelo-Donovan DD, Dickson-Witmer D, Petrelli NJ. Sentinel lymph node biopsy in breast cancer: a history and current clinical recommendations. Surg Oncol. 2012;21:196–200.
5. McLachlin SA, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008;26(32):5213–9.
6. Erickson VS, Pearson ML, Ganz PA, et al. Arm edema in breast cancer patients. J Natl Cancer Inst. 2001;93:96–111.
7. Veronesi U, Stafylidou V, Luiuand A, et al. Breast cancer from “maximum tolerable” to “minimum effective” treatment. Front Oncol. 2012;2:1–5.
8. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.
9. Krag DN, Weaver DL, Alex JC, et al. Surgical resection and radio-localization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2:335–40.
10. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–401.
11. Giuliano AE, Jones RC, Brennan M, et al. Sentinel lymphadenectomy in breast cancer. Clin Oncol. 1997;15:2345–50.
12. Veronesi U, Paganielli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997;349:1864–7.
13. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006; 1064–16.
14. Simmons RM, Smith SMR, Osborne MP. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Breast J 2001;7:181–3.
15. Simmons R, Thevarajah S, Brennan MB, et al. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Ann Surg Oncol. 2003;10:242–7.
16. Varghese P, Mostafa A, Abdel-Rahman AT, et al. Methylene blue dye versus combined dye-radioactive tracer technique for sentinel lymph node localization in early breast cancer. EJSO. 2007;33:147–52.
17. Blessing WD, Stolier AJ, Teng SC, et al. A comparison of methylene blue and lymphazurin in breast cancer sentinel node mapping. Am J Surg 2002;184:341–5.
18. Zakaria S, Hoskin Tl, Degnim AC. Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. Am J Surg. 2008;196:228–33.
19. Mathelin C, Croce S, Brasse D, et al. Methylene blue dye, an accurate dye for sentinel lymph node identification in early breast cancer. Cancer Res. 2009; 69:419–26.
20. Nour A. Efficacy of methylene blue dye in localization of sentinel lymph node in breast cancer patients. Breast J. 2004;10:388–91.
21. Golshan M, Nakhil F. Can methylene blue only be used in sentinel lymph node biopsy for breast cancer? Breast J. 2006;12:428–30.
22. Thevarajah S, Huston TL, Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am J Surg. 2005;189:236–9.
23. Brahma B, Haryono SJ, Ramadhan, et al. Methylene blue dye as a single agent in breast cancer sentinel lymph node biopsy: initial study of cancer centre hospital (Abstract). Accepted in 19th Asian Congress of Surgery & 1st SingHealth Surgical Congress. 2013.
24. Colditz G, Chia KS. Invasive breast carcinoma: introduction and general features. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. World Health Organization classification of tumours of the breast. Lyon; IARC Press; 2012. p. 13–31.
25. Colak D, Nofal A, AlBahkeeth A, et al. Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS ONE. 2013;8:1–15.
26. Weaver DL. Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale. Modern Pathol. 2010;23:526–32.
27. Zurrida S, Veronesi U. Milestones in breast cancer treatment. Breast J. 2015;21:3–12.
28. Giuliano AE, Gangi A. Sentinel node biopsy and improved patient care. Breast J. 2015;21:27–31.
29. Wibodo I, Dwianingsih TH, Trisinsih P, et al. Clinicopathological features of Indonesian breast cancers with different molecular subtypes. Asian Pac J Cancer Prev. 2014;15:6109–13.
30. Ahmad M, Purushotham AD, Donek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol. 2014;15:e351–62.
31. Fattahi AS, Davassi AS, Rohbakhshfar O, et al. Can methylene blue dye be used as an alternative to patent blue dye to find the sentinel lymph node in breast cancer surgery? J Res Med Sci. 2014;19:918–22.
32. Liu Y, Tran C, Arjan S. A randomized study comparing the effectiveness of methylene blue dye with lymphazurin blue dye in sentinel lymph node biopsy for the treatment of cutaneous melanoma. Ann Surg Oncol. 2008;15:2412–7.
33. Bonnaeau C, Bendifallah S, Reyal F, et al. Association of the number of sentinel lymph nodes harvested with survival in breast cancer. EJSO. 2015; 41:52–8.
34. Goyal A, Newcombe RG, Mansell RE. Clinical relevance of multiple sentinel nodes in patients with breast cancer. Br J Surg. 2005;92:438–42.
35. Kennedy RJ, Kollia A, Gill PG, et al. Removal of two sentinel nodes accurately stages the axilla in breast cancer. Br J Surg. 2003;90:1349–53.
36. Wong SL, Edwards MJ, Chao C, et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg. 2001;192:684–91.
37. McCarter MD, Yeung H, Fey J, et al. The breast cancer patient with multiple sentinel nodes: when to stop? J Am Coll Surg. 2001;192:692–7.
38. Abdessalam SF, Zervos EE, Prasad M, et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg. 2001;182:316–20.
39. Rahusen FD, Torrenga H, van Diest PJ, et al. Predictive factors for metastatic involvement of nonsentinel nodes in patients with breast cancer. Arch Surg. 2001;136:1059–63.
40. Van Zee KJ, Manasseh DE, Bevilacqua JLB, et al. A nomogram for predicting the likelihood of additional nodal metastasis in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140–51.
41. Meretoja TJ, Leidenius MHK, Heikkila PS, et al. International multicenter tool to predict the risk of nonsentinel node metastases in breast cancer. J Natl Cancer Inst. 2012;104:1888–96.
42. Degnim AC, Reynolds C, Pantyaidya G, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg. 2005;190:543–50.
43. Kohrt HE, Olsken RA, Bemsa HR, Goodson WH, Wood DJ, Henry S, et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node-positive breast cancer patients. BMC Cancer. 2008;8:1–15.
44. Giuliani AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.
45. Galimberti V, Cole BF, Zuniga S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. The lancet oncology. 2013;14(4):297–305.
46. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–20023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10.
47. Goyal A, Dodwell D, POSNOC, a randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases. Clin Oncol. 2015;27:692–5.
48. Canavesel G, Cattarich A, Vecchioli C, et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol. 2009;20:1001–7.
49. Zavagno G, Salvo GLD, Scalco G, et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GNOM trials. Ann Surg. 2008;247:207–13.
50. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–8.
51. Goyal A, Newcombe RG, Chhabra A, et al. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer—results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006;99:203–8.
52. Cox CE, Dupont E, Whitehead GF, Ebert MD, Nguyen K, Peltz ES, Peckham D, Cantor A, Reintgen DS. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast. 2002;9:82(188–91).
53. Kaulich DG, Keil MR, Ruecklinger E, Singer CF, Seiffert M, Kubista E. Factors influencing the identification rate of the sentinel node in breast cancer. Eur J Cancer Care. 2011;20(5):627–31.
54. Chagpar AB, Martin KC, Scoggins CR, Carlson DJ, Laidley AL, El-Eid SE, McGlothlin TQ, Noyes RD, Ley PB, Tuttle TM, McMasters KM. Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery. 2005;138(1):56–63.
55. Strading B, Aranha G, Gabram S. Adverse skin lesions after methylene blue injections for sentinel lymph node localization. Am J Surg. 2002;184:350–2.